Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Devices & Implants
- Sub-Industry: N/A
- Symbol: NASDAQ:EYES
- CUSIP: N/A
- Web: www.secondsight.com
Capitalization:- Market Cap: $63.61 million
- Outstanding Shares: 56,794,000
Average Prices:- 50 Day Moving Avg: $1.11
- 200 Day Moving Avg: $1.20
- 52 Week Range: $0.90 - $3.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.21
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $5.14 million
- Price / Sales: 12.71
- Book Value: $0.33 per share
- Price / Book: 3.48
Profitability:- EBIDTA: ($32,850,000.00)
- Net Margins: -646.89%
- Return on Equity: -168.49%
- Return on Assets: -129.48%
Debt:- Current Ratio: 4.18%
- Quick Ratio: 3.62%
Misc:- Average Volume: 388,078 shs.
- Beta: 3.61
- Short Ratio: 9.99
Frequently Asked Questions for Second Sight Medical Products (NASDAQ:EYES)
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products, Inc. (NASDAQ:EYES) issued its earnings results on Tuesday, August, 1st. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. The firm earned $2.24 million during the quarter, compared to analyst estimates of $1.43 million. Second Sight Medical Products had a negative net margin of 646.89% and a negative return on equity of 168.49%. The company's quarterly revenue was up 124.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) earnings per share. View Second Sight Medical Products' Earnings History.
When will Second Sight Medical Products make its next earnings announcement?
Where is Second Sight Medical Products' stock going? Where will Second Sight Medical Products' stock price be in 2017?
1 brokerages have issued 12 month price targets for Second Sight Medical Products' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next year. View Analyst Ratings for Second Sight Medical Products.
What are analysts saying about Second Sight Medical Products stock?
Here are some recent quotes from research analysts about Second Sight Medical Products stock:
- 1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (9/13/2017)
- 2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include Oramed Pharmaceuticals (ORMP), Cidara Therapeutics (CDTX), Axsome Therapeutics (AXSM), BioLineRx (BLRX), Cumberland Pharmaceuticals (CPIX), Viveve Medical (VIVE), VIVUS (VVUS), Dimension Therapeutics (DMTX), Otonomy (OTIC), iRadimed Corporation (IRMD), Neovasc (NVCN), Medicure (MCUJF), MEI Pharma (MEIP), NOVAN INC (NOVN), Galmed Pharmaceuticals (GLMD), Affimed N.V. (AFMD), CytoDyn (CYDY) and Gemphire Therapeutics (GEMP).
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the folowing people:
- Robert J. Greenberg M.D. Ph.D., Chairman of the Board
- Jonathan McGuire, President, Chief Executive Officer, Director
- Stephen D. Okland Jr., Commercial Vice President, U.S. and Canada
- Edward David Randolph, Vice President - Manufacturing
- David Murray Jacques, Vice President - Research & Development
- Gregoire Cosendai, Vice President - European Operations
- William J. Link Ph.D., Independent Director
- Aaron Mendelsohn, Independent Director
- Matthew Jonathan Pfeffer, Independent Director
- Gregg Williams, Independent Director
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.
Who owns Second Sight Medical Products stock?
Second Sight Medical Products' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.97%), Vanguard Group Inc. (1.50%), BNP Paribas Arbitrage SA (0.79%) and Carl Domino Inc (0.20%). Company insiders that own Second Sight Medical Products stock include Anne-Marie Juliette Ripley, Edward David Randolph, Gregg Williams and Robert J Greenberg. View Institutional Ownership Trends for Second Sight Medical Products.
Who sold Second Sight Medical Products stock? Who is selling Second Sight Medical Products stock?
Who bought Second Sight Medical Products stock? Who is buying Second Sight Medical Products stock?
How do I buy Second Sight Medical Products stock?
Shares of Second Sight Medical Products can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical Products' stock price today?
One share of Second Sight Medical Products stock can currently be purchased for approximately $1.15.
MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Second Sight Medical Products (NASDAQ:EYES) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $5.00 (334.78% upside) |
Analysts' Ratings History for Second Sight Medical Products (NASDAQ:EYES)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/29/2017 | HC Wainwright | Set Price Target | Buy | $5.00 | Low |  |
| 7/26/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $16.00 | N/A | |
(Data available from 9/19/2015 forward)
Earnings History for Second Sight Medical Products (NASDAQ:EYES)Earnings History by Quarter for Second Sight Medical Products (NASDAQ EYES)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.14) | | | | | N/A | |
| 8/1/2017 | Q2 2017 | ($0.14) | ($0.13) | $1.43 million | $2.24 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.14) | ($0.18) | $1.32 million | $1.01 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.17) | ($0.24) | $1.76 million | $0.72 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.16) | ($0.15) | $2.36 million | $1.20 million | View | N/A | |
| 7/28/2016 | Q216 | ($0.15) | ($0.17) | $2.66 million | $1.04 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.16) | ($0.13) | $1.38 million | $1.05 million | View | Listen | |
| 3/3/2016 | Q415 | ($0.14) | ($0.15) | $2.47 million | $2.40 million | View | N/A | |
| 10/29/2015 | Q315 | ($0.14) | ($0.13) | $2.05 million | $2.23 million | View | Listen | |
| 8/4/2015 | Q215 | ($0.14) | ($0.14) | $1.73 million | $2.70 million | View | N/A | |
| 5/13/2015 | Q115 | | ($0.12) | | $1.70 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Second Sight Medical Products (NASDAQ:EYES)Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS
Dividend History for Second Sight Medical Products (NASDAQ:EYES)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Second Sight Medical Products (NASDAQ:EYES)Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 13.07%
Insider Trades by Quarter for Second Sight Medical Products (NASDAQ:EYES)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/7/2017 | Gregg Williams | Director | Buy | 4,000,000 | $1.00 | $4,000,000.00 | |
| 12/1/2016 | Robert J Greenberg | Chairman | Sell | 1,950 | $1.96 | $3,822.00 | |
| 6/3/2016 | Edward David Randolph | VP | Sell | 5,104 | $4.01 | $20,467.04 | |
| 6/2/2016 | Robert J Greenberg | Chairman | Sell | 8,571 | $4.10 | $35,141.10 | |
| 4/18/2016 | Robert J Greenberg | Chairman | Sell | 8,223 | $5.27 | $43,335.21 | |
| 12/7/2015 | Robert J. Greenberg | Chairman | Sell | 17,969 | $5.30 | $95,235.70 | |
| 12/4/2015 | Anne-Marie Juliette Ripley | VP | Sell | 2,500 | $5.50 | $13,750.00 | |
| 6/4/2015 | Anne-Marie Juliette Ripley | VP | Sell | 4,371 | $15.00 | $65,565.00 | |
| 6/3/2015 | Robert J Greenberg | CEO | Sell | 150,000 | $14.04 | $2,106,000.00 | |
| 5/27/2015 | Anne-Marie Juliette Ripley | VP | Sell | 45,629 | $13.04 | $595,002.16 | |
| 3/23/2015 | Robert J Greenberg | CEO | Sell | 100,000 | $13.28 | $1,328,000.00 | |
| 11/19/2014 | Gregg Williams | Director | Buy | 111,111 | $9.00 | $999,999.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Second Sight Medical Products (NASDAQ:EYES)
Latest Headlines for Second Sight Medical Products (NASDAQ:EYES)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Analysis: Second Sight Medical Products (EYES) versus Stryker Corporation (SYK)
www.americanbankingnews.com - September 16 at 12:10 AM |
| Second Sight Medical Products, Inc. (EYES) Upgraded at Zacks Investment Research
www.americanbankingnews.com - September 13 at 10:26 PM |
| Cyberonics (CYBX) vs. Second Sight Medical Products (EYES) Head-To-Head Analysis
www.americanbankingnews.com - September 13 at 4:30 PM |
| St Jude Medical (STJ) and Second Sight Medical Products (EYES) Critical Contrast
www.americanbankingnews.com - September 8 at 8:28 PM |
 | Annual Rodman & Renshaw Global Investment Conference in New York on September 12 - Business Wire (press release)
www.businesswire.com - September 5 at 8:14 PM |
 | Second Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12th
finance.yahoo.com - September 5 at 8:13 PM |
| Critical Contrast: Second Sight Medical Products (EYES) & RTI Surgical (RTIX)
www.americanbankingnews.com - August 30 at 12:18 PM |
| Financial Comparison: Second Sight Medical Products (EYES) & ConforMIS (CFMS)
www.americanbankingnews.com - August 29 at 6:18 PM |
| Second Sight Medical Products' (EYES) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - August 29 at 7:58 AM |
 | Second Sight Stock Climbs on FDA Nod
www.baystreet.ca - August 28 at 6:15 PM |
| Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study
finance.yahoo.com - August 28 at 6:15 PM |
| Analyzing Second Sight Medical Products (EYES) and Glaukos Corporation (GKOS)
www.americanbankingnews.com - August 19 at 2:26 AM |
| Second Sight Medical Products, Inc. (EYES) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 10 at 9:06 PM |
| Head-To-Head Survey: Second Sight Medical Products (NASDAQ:EYES) vs. Trivascular Technologies (TRIV)
www.americanbankingnews.com - August 10 at 8:22 PM |
 | Second Sight Medical Products' (EYES) CEO Will McGuire on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 2 at 5:13 AM |
| Second Sight Medical Products, Inc. (EYES) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 1 at 9:29 PM |
| Investor Network: Second Sight Medical Products, Inc. to Host Earnings Call
finance.yahoo.com - August 1 at 7:07 PM |
| Second Sight Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 7:07 PM |
| Second Sight Medical Products posts 2Q loss
finance.yahoo.com - August 1 at 7:07 PM |
 | Form 8-K SECOND SIGHT MEDICAL For: Jul 26 - StreetInsider.com
www.streetinsider.com - July 28 at 4:41 PM |
| Second Sight Medical (EYES) Reports First Implant of Argus II Retinal Prosthesis in Russia
www.streetinsider.com - July 27 at 5:13 AM |
| Second Sight Medical (EYES) Reports First Implant of Argus II Retinal Prosthesis in Russia - StreetInsider.com
www.streetinsider.com - July 26 at 7:08 PM |
| Second Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System
finance.yahoo.com - July 26 at 7:07 PM |
| Second Sight Medical Products, Inc. (NASDAQ:EYES) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 25 at 8:04 AM |
| Second Sight to Discuss Second Quarter 2017 Financial Results on August 1, 2017 Conference Call - Business Wire (press release)
www.businesswire.com - July 20 at 9:58 PM |
| Second Sight to Discuss Second Quarter 2017 Financial Results on August 1, 2017 Conference Call
finance.yahoo.com - July 20 at 9:58 PM |
| Second Sight Medical Products (EYES)
seekingalpha.com - July 16 at 10:27 AM |
| Second Sight enters South Korea, two patients implanted with Argus II - Seeking Alpha
seekingalpha.com - July 12 at 12:44 AM |
| Second Sight Medical Products, Inc. (EYES) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - July 6 at 7:46 AM |
| Second Sight Announces Market Entry into South Korea with Two Implants and Performs Second Implant in Taiwan of Argus II Retinal Prosthesis System
finance.yahoo.com - July 5 at 7:11 PM |
 | BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Bankrate, Rice Energy ... - Nasdaq
www.nasdaq.com - July 4 at 4:22 AM |
 | 10 Biggest Mid-Day Gainers For Monday - Benzinga
www.benzinga.com - July 4 at 4:22 AM |
| Second Sight Medical (EYES) Gains as Medicare Coverage for ... - StreetInsider.com
www.streetinsider.com - July 4 at 4:22 AM |
| Second Sight Medical (EYES) Gains as Medicare Coverage for Argus II Expands
www.streetinsider.com - July 3 at 6:20 PM |
| Second Sight Announces Expansion of Medicare Coverage for Argus II Retinal Prosthesis System to 11 Additional States and the District of Columbia
finance.yahoo.com - July 3 at 6:20 PM |
| ETFs with exposure to Second Sight Medical Products, Inc. : June 28, 2017
finance.yahoo.com - June 28 at 6:12 PM |
| Second Sight Medical (EYES) CFO to Resign to Pursue Other ... - StreetInsider.com
www.streetinsider.com - June 26 at 11:10 PM |
| ETFs with exposure to Second Sight Medical Products, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 3:56 PM |
| ETFs with exposure to Second Sight Medical Products, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 5:45 PM |
 | Research Reports Initiation on Medical Equipment Stocks -- Corindus Vascular Robotics, InspireMD, Xtant Medical ... - PR Newswire (press release)
www.prnewswire.com - May 23 at 4:49 PM |
| Second Sight to Present at 18th Annual B. Riley & Co. Institutional ... - Business Wire (press release)
www.businesswire.com - May 17 at 5:08 PM |
| Second Sight to Present at 18th Annual B. Riley & Co. Institutional Investor Conference
finance.yahoo.com - May 17 at 10:48 AM |
| ETFs with exposure to Second Sight Medical Products, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:47 PM |
| Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:39 PM |
| Second Sight Medical Products Inc (EYES) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 11 at 9:36 PM |
| Second Sight Medical Products Inc (EYES) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:54 PM |
| Second Sight Medical Products' (EYES) CEO Will McGuire on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 4 at 5:16 PM |
| Second Sight Medical Products (EYES) Receiving Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 9:20 AM |
 | Second Sight Medical Products posts 1Q loss
marketbeat.com - May 3 at 5:26 PM |
| Second Sight Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 4:57 PM |
Second Sight Medical Products (EYES) Chart for Tuesday, September, 19, 2017
